According to the GLOBOCAN 2020 project, breast, cervical, ovarian and uterine cancers are among the top 10 most common cancers in women worldwide. It is estimated that breast cancer in women has become the most common cancer, surpassing lung cancer globally. A growing body of evidence suggests that multiple factors are associated with the development and progression of cancer in women. Despite significant achievements in early diagnosis and treatment strategies, breast cancer continues to be of great concern worldwide due to its high incidence and mortality rates. The unsatisfactory clinical outcomes are mainly due to tumor recurrence, metastasis and treatment resistance. Cervical cancer is the second most common cancer in women in developing countries. Preoperative neoadjuvant chemotherapy based on paclitaxel can effectively reduce tumor burden and decrease micrometastases, allowing more cervical cancer patients to have access to surgical treatment. However, chemoresistance has become a common clinical concern. Identification of novel biomarkers associated with molecular subtypes, aggressive phenotypes and prognosis of breast cancer is essential for drug development, disease surveillance and precise treatment. At this stage, imaging techniques and the use of biochemical biomarkers, such as proteins, DNA, mRNA and microRNA, can be used as new diagnostic and therapeutic tools for women's cancers.
This research topic will focus on various imaging techniques and biochemical biomarkers that can be used to diagnose patients with breast, cervical, ovarian and uterine cancers. In addition, with the development of bioinformatics, gene expression profiling has been used in clinical practice for treatment decisions in patients with early-stage cancer. Patients with high-risk may benefit from adjuvant chemotherapy, while those with low-risk may avoid unnecessary treatment. In addition, liquid biopsy sampling, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free RNA, tumor-cultured platelets, and exosomes, can be used to enhance individualized therapy and longitudinal screening.
We welcome submissions of Original Research, Systematic Review, Clinical Trial, Commentaries and Short Reports, on the subtopics of the following, but are not limited to:
● Imaging techniques and biochemical biomarkers that could be utilized for the diagnosis of patients with breast cancer, cervical cancer, ovarian cancer, and uterine cancer
● Bioinformatics-based predictive models for the treatment and prognosis of women’s cancers. Essential experiments are needed to validate in silico conclusions.
● The advantages and limitations of the various biomarkers used in breast cancer diagnosis and the aspects that require further focus in future research.
● The future direction of liquid biopsy in the diagnosis of women’s cancers.
According to the GLOBOCAN 2020 project, breast, cervical, ovarian and uterine cancers are among the top 10 most common cancers in women worldwide. It is estimated that breast cancer in women has become the most common cancer, surpassing lung cancer globally. A growing body of evidence suggests that multiple factors are associated with the development and progression of cancer in women. Despite significant achievements in early diagnosis and treatment strategies, breast cancer continues to be of great concern worldwide due to its high incidence and mortality rates. The unsatisfactory clinical outcomes are mainly due to tumor recurrence, metastasis and treatment resistance. Cervical cancer is the second most common cancer in women in developing countries. Preoperative neoadjuvant chemotherapy based on paclitaxel can effectively reduce tumor burden and decrease micrometastases, allowing more cervical cancer patients to have access to surgical treatment. However, chemoresistance has become a common clinical concern. Identification of novel biomarkers associated with molecular subtypes, aggressive phenotypes and prognosis of breast cancer is essential for drug development, disease surveillance and precise treatment. At this stage, imaging techniques and the use of biochemical biomarkers, such as proteins, DNA, mRNA and microRNA, can be used as new diagnostic and therapeutic tools for women's cancers.
This research topic will focus on various imaging techniques and biochemical biomarkers that can be used to diagnose patients with breast, cervical, ovarian and uterine cancers. In addition, with the development of bioinformatics, gene expression profiling has been used in clinical practice for treatment decisions in patients with early-stage cancer. Patients with high-risk may benefit from adjuvant chemotherapy, while those with low-risk may avoid unnecessary treatment. In addition, liquid biopsy sampling, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free RNA, tumor-cultured platelets, and exosomes, can be used to enhance individualized therapy and longitudinal screening.
We welcome submissions of Original Research, Systematic Review, Clinical Trial, Commentaries and Short Reports, on the subtopics of the following, but are not limited to:
● Imaging techniques and biochemical biomarkers that could be utilized for the diagnosis of patients with breast cancer, cervical cancer, ovarian cancer, and uterine cancer
● Bioinformatics-based predictive models for the treatment and prognosis of women’s cancers. Essential experiments are needed to validate in silico conclusions.
● The advantages and limitations of the various biomarkers used in breast cancer diagnosis and the aspects that require further focus in future research.
● The future direction of liquid biopsy in the diagnosis of women’s cancers.